BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32699075)

  • 1. Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network.
    Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
    Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2524-2540. PubMed ID: 32699075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelioma Biomarkers: Discovery in Search of Validation.
    Pass HI; Alimi M; Carbone M; Yang H; Goparaju CM
    Thorac Surg Clin; 2020 Nov; 30(4):395-423. PubMed ID: 33012429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and prognosis-review of biomarkers for mesothelioma.
    Sun HH; Vaynblat A; Pass HI
    Ann Transl Med; 2017 Jun; 5(11):244. PubMed ID: 28706912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
    Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.
    Santarelli L; Strafella E; Staffolani S; Amati M; Emanuelli M; Sartini D; Pozzi V; Carbonari D; Bracci M; Pignotti E; Mazzanti P; Sabbatini A; Ranaldi R; Gasparini S; Neuzil J; Tomasetti M
    PLoS One; 2011 Apr; 6(4):e18232. PubMed ID: 21483773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
    Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for malignant pleural mesothelioma: current status.
    Greillier L; Baas P; Welch JJ; Hasan B; Passioukov A
    Mol Diagn Ther; 2008; 12(6):375-90. PubMed ID: 19035624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
    Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
    EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
    Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
    Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum mesothelin and other biomarkers: what have we learned in the last decade?
    Cristaudo A; Bonotti A; Guglielmi G; Fallahi P; Foddis R
    J Thorac Dis; 2018 Jan; 10(Suppl 2):S353-S359. PubMed ID: 29507805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The established and future biomarkers of malignant pleural mesothelioma.
    Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
    Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.